SkinHealth Systems (SKIN) Stock
SkinHealth Systems's price implies about -24% free cash flow growth a year.
Key numbers
- P/E (forward)
- 4.39x
- EV / EBITDA
- 8.20x
- Revenue growth
- -4.4%
- Operating margin
- 2.4%
- Debt / equity
- 4.36x
What SkinHealth Systems's price implies
From a reverse DCF on SkinHealth Systems's SEC filings.
- Free cash flow, last 2 years
- 44.0%a year
- Revenue, same period
- 10.3%a year
At a market value of $102M, SkinHealth Systems's free cash flow of $37M (fiscal 2025) would need to grow about -24% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 2 years. A 9% discount rate and 3% growth after year 10 (how it works). Change them in the Modeling tab or the reverse DCF calculator.
Revenue and free cash flow
Fiscal years, from SkinHealth Systems's 10-K filings.
SkinHealth Systems revenue and free cash flow
FY2019–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $260M | $366M | $398M | $334M | $301M |
| Net income | -$379M | $44M | -$100M | -$29M | -$10M |
| Free cash flow | -$40M | -$117M | $18M | $15M | $37M |
| EPS (diluted) | -$74.20 | -$4.60 | -$15.20 | -$7.20 | -$3.20 |
| Operating margin | -15.4% | -7.1% | -32.9% | -20.3% | -6.9% |
Where the revenue comes from
By products, fiscal 2025. By year
Superinvestors who own SKIN
From each investor's latest 13F filing (what a 13F shows).
None of the superinvestors we track held SKIN in their latest 13F.
SkinHealth Systems insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of SKIN in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from SKIN's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How SkinHealth Systems compares
SkinHealth Systems's P/FCF is higher than 9% of Consumer Defensive companies and 10% of the 2,359 companies with a P/FCF figure.
| Higher than | Consumer Defensive | All stocks |
|---|---|---|
| P/FCF | 9% | 10% |
| Revenue growth | 13% | 14% |
| Operating margin | 30% | 33% |
| ROE | 4% | 13% |
Questions about SkinHealth Systems
What growth does SkinHealth Systems's stock price imply?
At a market value of $102M, SkinHealth Systems would need its free cash flow to grow about -24% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 2 years its free cash flow grew 44% a year.
Are SkinHealth Systems insiders buying the stock?
No open-market insider purchases of SKIN in the last 12 months, according to SEC Form 4 filings.
Companies like SkinHealth Systems
Yatsen Holding Ltd (YSG)$173MNU Skin Enterprises, Inc. (NUS)$200MAcme United Corporation (ACU)$262MMagnera Corp (MAGN)$442MHonest Company Inc (HNST)$545MHelen of Troy Ltd (HELE)$872MOddity Tech Ltd (ODD)$1.2BEdgewell Personal Care Co (EPC)$1.3BSpectrum Brands Holdings Inc (SPB)$2.0B All Consumer Defensive stocks→Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.